463 related articles for article (PubMed ID: 30154155)
21. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
22. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Warsch W; Kollmann K; Eckelhart E; Fajmann S; Cerny-Reiterer S; Hölbl A; Gleixner KV; Dworzak M; Mayerhofer M; Hoermann G; Herrmann H; Sillaber C; Egger G; Valent P; Moriggl R; Sexl V
Blood; 2011 Mar; 117(12):3409-20. PubMed ID: 21220747
[TBL] [Abstract][Full Text] [Related]
23. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
24. Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
Yuanxin Y; Yanhong Z; Qin Z; Sishi T; Yang D; Yi Z; Minjin W; Juan Z; Xiaojun L; Lanlan W; Binwu Y
Leuk Res; 2019 Apr; 79():6-16. PubMed ID: 30784762
[TBL] [Abstract][Full Text] [Related]
25. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
26. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
Hjort EE; Huang W; Hu L; Eklund EA
Oncotarget; 2016 Nov; 7(47):77635-77650. PubMed ID: 27769062
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
28. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
[TBL] [Abstract][Full Text] [Related]
29. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
[TBL] [Abstract][Full Text] [Related]
30. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
31. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
32. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.
Bibi S; Arslanhan MD; Langenfeld F; Jeanningros S; Cerny-Reiterer S; Hadzijusufovic E; Tchertanov L; Moriggl R; Valent P; Arock M
Haematologica; 2014 Mar; 99(3):417-29. PubMed ID: 24598853
[TBL] [Abstract][Full Text] [Related]
33. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract][Full Text] [Related]
34. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.
Irwin ME; Nelson LD; Santiago-O'Farrill JM; Knouse PD; Miller CP; Palla SL; Siwak DR; Mills GB; Estrov Z; Li S; Kornblau SM; Hughes DP; Chandra J
PLoS One; 2013; 8(8):e70608. PubMed ID: 23936456
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
[TBL] [Abstract][Full Text] [Related]
36. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
37. The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
Putri A; Rinaldi I; Louisa M; Koesnoe S
Acta Med Indones; 2019 Oct; 51(4):348-352. PubMed ID: 32041920
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
39. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
40. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
